Our commitment to improving patient outcomes
As an innovative biopharmaceutical company, we partner, raise awareness and broaden scientific exchange around testing to improve patient outcomes.
Through science, and partnership, we work with other experts in diagnostics and genetics to improve lab-to-diagnosis procedures; and ultimately help more patients be quickly and appropriately diagnosed and treated, so the right therapy matches the right patient.
Personalised healthcare: transforming the way we use medicine
Personalised healthcare is at the heart of AstraZeneca’s approach to discovering and developing medicines, because we believe in the value it can deliver. This is reflected in our pipeline, with approximately 80% of our programmes benefiting from a personalised healthcare or biomarker platform.
The approach involves a detailed understanding of the biology of a disease, identifying biomarkers and developing tests, known as companion diagnostics, which doctors can use to identify who is most likely to respond to treatment with a targeted therapy.
Precision medicine: focused on the delivery of targeted therapies
At AstraZeneca, our commitment to precision medicine involves development of partnerships to deliver targeted therapies and companion diagnostics to markets around the world. Our partnerships with academia, governments, industry and scientific organisations allow us to access the best science, the most advanced technology, and the greatest expertise to successfully bring our medicines to patients.
Our teams seek to follow the science by collaborating with a wide range of expert partners to identify, validate, manufacture, and commercialise diagnostics, and biomarker capabilities, with the ultimate goal of delivering precision medicines to patients.
Areas of interest include:
- Methodology for patient selection
- Disease identification
- Pharmacological assessment
- Drug response monitoring
- Patient access
- Distribution of diagnostics
Page Atlas ID: 998917.011
Date of next review: July 2017